论文部分内容阅读
目的分析HIV/AIDS患者抗病毒治疗前后CD4~+T淋巴细胞数的变化情况,为全省的抗病毒治疗提供科学依据。方法对青海省2013—2015年间接受抗病毒治疗的127名HIV/AIDS患者治疗前、治疗后3个月、6个月、9个月及12个月CD4~+T淋巴细胞数进行检测和统计学分析。结果 127例HIV/AIDS患者的平均开始治疗年龄为(37.6±10.8)岁,治疗前CD4~+T淋巴细胞数平均水平为(321.2±108.4)个/μL;患者治疗3个月、6个月、9个月和12个月时与进入治疗时点相比,其CD4~+T淋巴细胞数平均增加了52.2个/μL、75.8个/μL、75.3个/μL和76.5个/μL,差异均有统计学意义(P<0.01);经抗病毒治疗1年后,CD4~+T淋巴细胞数>500个/μL的患者从0例增至37例,占患者总数的29.1%;CD4~+T淋巴细胞数分为≤200个/μL、201~350个/μL和>350个/μL三组患者,经抗病毒治疗1年后,CD4~+T淋巴细胞数平均分别增加了80.7个/μL、84.7个/μL和65.8个/μL,不同组患者HAART治疗1年后CD4~+T淋巴细胞数均值变化差异有统计学意义(P均<0.05)。结论青海省目前的HAART治疗效果明显,同时提高HIV/AIDS患者的依从性,并尽早开展抗病毒治疗,有利于提高患者的生命质量,延缓疾病进程,降低病死率。
Objective To analyze the changes of CD4 ~ + T lymphocytes before and after antiviral therapy in HIV / AIDS patients and provide a scientific basis for antiviral therapy in the province. Methods The number of CD4 ~ + T lymphocytes in 127 HIV / AIDS patients receiving antiretroviral therapy during 2013-2015 in Qinghai Province before treatment, 3 months, 6 months, 9 months and 12 months after treatment were detected and statistically analyzed Analysis. Results The mean age at onset of treatment for 127 HIV / AIDS patients was (37.6 ± 10.8) years old, with an average level of (321.2 ± 108.4) / μL before treatment. The patients treated for 3 months and 6 months , The average number of CD4 ~ + T lymphocytes increased by 52.2 / μL, 75.8 / μL, 75.3 / μL and 76.5 / μL at 9, 12 and 12 months, respectively (P <0.01). After 1 year of anti-virus treatment, the number of CD4 + T lymphocytes> 500 cells / μL increased from 0 to 37, accounting for 29.1% of the total number of patients. The number of T lymphocytes was divided into three groups of ≤200 / μL, 201 ~ 350 / μL and> 350 / μL. After 1 year of anti-virus therapy, the average number of CD4 ~ + T lymphocytes increased by 80.7 / μL, 84.7 cells / μL and 65.8 cells / μL. The mean CD4 ~ + T lymphocyte counts in HAART patients after one year of treatment were significantly different (all P <0.05). Conclusions The current HAART treatment in Qinghai Province is obvious, at the same time improving the compliance of HIV / AIDS patients and carrying out antiviral therapy as early as possible, which is beneficial to improve the quality of life of patients, delay the disease process and reduce the mortality.